SMALL CELL LUNG CANCER

This study tested a combination of two drugs (NT-I7 and pembrolizumab) in 215 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The goal was to find a safe dose and see if the combo could shrink tumors. The study also looked at imm…

This study tested whether adding the drug trilaciclib to standard chemotherapy and immunotherapy could protect bone marrow and the immune system in people with advanced small cell lung cancer. About 100 participants received either trilaciclib or a placebo alongside their cancer …

This early-stage study tested an experimental drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced solid tumors that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal was to check safety and find the rig…

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for their extensi…

This study looked at 45 people with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiotherapy. The goal was to see how long the cancer stayed under control and how safe the treatment was. Results from this real-world anal…

This study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were receiving chemotherapy. The goal was to see if giving trilaciclib before chemo could protect the bone marrow and immune system, reducing dangerous drops in white blood cells an…

This study tested a combination of two drugs (anlotinib and penpulimab) in 65 people with small cell lung cancer whose disease had worsened after initial chemotherapy. The goal was to see if the combination could shrink tumors and help people live longer. The approach aims to con…

This early-phase study tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, or lung cancer) that had stopped responding to standard treatments. The drug is a nanoparticle version of SN-38, a chemotherapy agent, given by IV on days 1 a…

This early-stage study tested a combination of two drugs, tarlatamab and AMG 404, in 23 adults with small cell lung cancer that had returned after standard treatment. The main goal was to check safety and find the best dose for future studies. This is not a cure, but aims to cont…

This study tested a special nursing program for people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program involved a team of nurses, dietitians, and mental health experts who monitored side effects, supported medication adherence, and prov…

This study looked at whether a new type of PET/CT scan can help predict how well patients with limited-stage small cell lung cancer will respond to standard chemotherapy and radiation. Thirty-three newly diagnosed patients had the scan before starting treatment. Researchers then …

This study looked at whether a simple blood test can detect genetic changes from lung cancer tumors. Researchers tested 200 patients with non-small cell or small cell lung cancer to see if the test could track how the disease changes over time. The goal was to find a less invasiv…